Sermorelin Acetate 10mg Research Peptide
Sermorelin (GHRH 1-29 NH2) is a synthetic peptide corresponding to the first 29 amino acids of endogenous growth hormone-releasing hormone (GHRH), representing the minimal active fragment required for full GHRH receptor activation and GH stimulation. It was the first GHRH analogue to receive FDA approval (1997, brand name Geref) for the treatment of idiopathic growth hormone deficiency in children, and was also approved as a diagnostic agent for GH secretory capacity assessment. Though withdrawn from the US market in 2008 due to commercial rather than safety reasons, sermorelin has a well-documented clinical profile and remains an important reference compound for GHRH receptor research. This 10mg vial provides research-grade Sermorelin Acetate at ≥99% purity, HPLC and MS/MS verified per batch.
Research Background
Sermorelin’s FDA approval history provides researchers with a clinical dataset rarely available for GHRH analogues. As the shortest active GHRH fragment, it is used as a reference compound for structure-activity relationship studies examining which GHRH residues are required for receptor binding and GH stimulation. Comparative research with longer analogues including tesamorelin (full 44-amino acid GHRH) and modified GRF 1-29 (CJC-1295 without DAC) uses sermorelin as a baseline for evaluating half-life, receptor affinity, and GH pulse characteristics across the GHRH analogue family.
Compound Specifications
- Format: Lyophilized powder (acetate salt)
- Purity: ≥99% (HPLC verified)
- Quantity: 10mg per vial
- Storage: −20°C, protected from light
- Sequence: GHRH (1-29) NH2
- Molecular Weight: 3357.9 Da
Certificate of Analysis
All Sermorelin Acetate vials are third-party tested by independent ISO-certified laboratories. HPLC and MS/MS validation performed per batch. COA available on request.
For research and laboratory use only. Not for human consumption. Not intended to diagnose, treat, cure, or prevent any disease.
